How many investments has Lumira Ventures made?

Lumira Ventures has 61 tracked investments, 5 of which have exited, including 7 dated in the last 24 months.

What stage does Lumira Ventures invest at?

Lumira Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is Lumira Ventures's typical check size?

Lumira Ventures typically writes checks of $1M – $10M.

What sectors does Lumira Ventures focus on?

Lumira Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.

Where is Lumira Ventures located?

Lumira Ventures is headquartered in Toronto, CA.

Who does Lumira Ventures co-invest with?

Lumira Ventures most often shares deals with New Enterprise Associates (NEA), SV Health Investors, Toronto Innovation Acceleration Partners, among 108 tracked co-investors.

Lumira Ventures

Venture capitaloperating company · company profile

Toronto · Pre-Seed–Late Stage · 18 people tracked

Also known as LUMIRA CAPITAL INVESTMENT MANAGEMENT INC.

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into Lumira Ventures

1,806 people in our graph share verified history with the Lumira Ventures team — schools, employers, funds. One of them is your warm intro.

Zhenyu Tangunlockedknows Jacki Jenuth · together at University of California, Berkeley, Haas School of Business (overlapped)

×2knows the team · via Creative Destruction Lab

knows the team · via ZS Associates

knows the team · via The Boston Consulting Group

knows the team · via McGill University

knows the team · via Harvard Medical School

✨ Fox Verdict

Investment thesis

Lumira Ventures backs mission-driven entrepreneurs building transformative life sciences companies. The firm focuses on developing and commercializing impactful products aimed at improving outcomes for patients, positioning itself as a leading North American life sciences investor.

Invests inBiotech Digital Health Healthtech Longevity Medical Devices Canada North America Toronto Toronto, Ontario United States

Source: firm website, verified Sep 15, 2026.

Stage

Pre-Seed–Late Stage

Check

$1M – $10M

Toronto, ON, CA

Instruments

Equity

Founded

2017

Last 12 months

3 investments

AUM

$500M

VC funds

Tracked investments

IPOs

Acquisitions

Team · 18 people

from the firm's website & public directories

Beni Rovinski· Managing Director· Toronto, Ontario, Canadain

Beni Rovinski holds a Ph.D. in Biochemistry and Molecular Biology from McGill University and completed post-doctoral training at the Ontario Cancer Institute. He spent 13 years in the pharmaceutical industry leading a global HIV/AIDS vaccine program before moving into life sciences venture capital, and helped lead a buy-out to build Lumira Ventures.

b•••@lumira.vcreveal

Peter van der Velden· Executive Chairman· Toronto, Ontario, Canadain

Van der Velden holds a master's degree in pathology and an MBA, and began his career at Connaught Biosciences, Canada's largest vaccine manufacturer, before joining the country's largest venture capital firm. At Lumira Ventures he focuses on healthcare companies and leads the firm's philanthropic engagement, and he took on a role transforming the CVCA (ACVM) in 2011.

p•••@lumira.vcreveal

Daniel Hétu· Managing Director

Daniel Hétu trained in medicine before completing an MBA, which shifted his career toward business. He worked in investment banking and later joined a fast-growing biotechnology company developing new drugs and vaccines. He is now a venture capitalist focused on science and innovation in the development of new therapeutics and medical devices.

Daniel Hetu· Managing Director

Daniel Hetu trained in medicine before pursuing an MBA, initially through night classes and then full time. He moved into investment banking with the goal of working in Canada's emerging biotech industry, and later joined a fast-growing biotech company developing drugs and vaccines. As a venture capitalist, he focuses on science and innovation related to the development of new drugs and medical devices.

d•••@lumira.vcreveal

Gerry Brunk· Managing Partner· Greater Bostonin

Gerry Brunk studied biology and business in college and graduate school before working in investment banking and healthcare management consulting. He co-founded and operated two startups, and since 2002 has worked as a venture capital investor. He focuses on the intersection of science, medicine, business, and impact, backing companies addressing disease.

g•••@lumira.vcreveal

Jacki Jenuth· Partner and COO· Toronto, Ontario, Canadain

Holds a PhD with post-doctoral studies at McGill and began his career at a venture-backed bioinformatics startup during the early genomics era. He joined Lumira's predecessor firm in an operating role building data analytics and computing infrastructure, and later took on investment responsibilities focused on neuroscience.

j•••@lumira.vcreveal

Lu Han· Partner· Torontoin

Lu Han holds a Ph.D. in neuroscience from the University of Toronto and previously co-founded a digital therapeutics company focused on neurological disorders. Raised in Suzhou, China, before moving to Canada at 15, Lu is a healthcare-focused investor at Lumira Ventures.

l•••@lumira.vcreveal

Nikhil Thatte· Partner· Torontoin

Nikhil Thatte works at Lumira Ventures, a healthcare-focused venture firm. He began at McGill University intending to become a doctor before shifting toward business, then spent four years at ZS Consulting serving large pharmaceutical companies and three years at DRI Capital acquiring healthcare royalty streams. He pursued an MBA at INSEAD before joining Lumira, and focuses on advancing medical innovation for patients.

n•••@lumira.vcreveal

Suman Rao· Principal· Canadain

Suman Rao holds a Ph.D. and completed a postdoctoral fellowship in cancer research before moving into management consulting advising biotech clients. She joined Lumira Ventures in 2021 to help build and support life science companies.

s•••@lumira.vcreveal

Dahlia Abbott· Accounting / Office Manager

Marc McCoy· Venture Clinician· Canadain

Marc McCoy is a clinical computational geneticist and resident physician at The Hospital for Sick Children who works at the intersection of computational science, artificial intelligence, biomedical research, and clinical medicine. His focus areas include trusted execution environments, genetic engineering, and cybersecurity across medical and industrial applications, with an emphasis on data sovereignty and patient privacy. He is interested in applying engineering approaches to diagnostic accuracy, treatment efficacy, and healthcare infrastructure development.

Marco Moya· IT Engineer· Toronto, Ontario, Canadain

Marco Moya is a System Engineer at Lumira Ventures with over 12 years of experience designing and implementing IT infrastructure solutions across on-premises and cloud environments. His background spans the pharmaceutical, retail, food, and financial sectors, where he has worked with technologies including VMware, Nutanix, Azure, Active Directory, Windows Server, PowerShell, Linux, and Citrix DaaS.

Michael Leung· Controller· Greater Toronto Area, Canadain

Theodore Witek· Special Advisor· Toronto, Ontario, Canadain

Theodore Witek is a Professor and Senior Fellow at the University of Toronto, where he directs Canada's first Doctor of Public Health Program. He brings decades of experience in pharmaceutical research, development, and executive leadership, including roles as Chief Scientific Officer and Chief Executive Officer across Europe and North America, along with involvement in major strategic alliances within the sector. His academic credentials include a Doctor of Public Health from Columbia University, an MPH from Yale University, and an MBA from Henley Management College, as well as an ICD.D designation and a Rotman Certified Executive Coach Certificate; he has served on numerous boards and committees, including as chair of committees at Innovative Medicines Canada and the American Thoracic Society, and has authored over 100 manuscripts and chapters on respiratory public health and drug development.

Danielle Karakas· Analyst· Toronto, Ontario, Canadain

d•••@lumira.vcreveal

Isabelle Harris· Associate· Toronto, Ontario, Canadain

Isabelle Harris holds degrees in genetics and business from the Ivey Business School and previously worked in management consulting in Boston before joining Lumira Ventures, where she focuses on life sciences investing.

i•••@lumira.vcreveal

Vasco Larcina· CFO· Toronto, Ontario, Canadain

v•••@lumira.vcreveal

Brent Norton

What they invest in

from 53 of 61 portfolio companies

Biotech ×40Healthtech ×33Medical Devices ×27Digital Health ×14Deep Tech ×9Hardware ×5AI & Machine Learning ×3Advanced Manufacturing ×1

HQs:United States×29Canada×5United Kingdom×1

Who they back

founder profiles across 23 portfolio companies

52%

solo founders

12 of 23 mapped founding teams

36%

repeat founders

of 22 founders with career history

~7 yrs

old at investment

median across 9 dated deals

Founding team size:solo founder×122 founders×63 founders×14+ founders×4

Where their founders studiedfrom 16 founders with education data

École de technologie supérieure ×3University of Toronto ×2

What their founders studiedfrom 19 founders with field-of-study data

Engineering ×9Life Sciences ×6Medicine ×5

Where their founders worked beforefrom 22 founders with career history

Dalhousie University ×4Sound Blade Medical Inc. ×2

9 founders hold a PhD · 1 hold an MBA (of 20 with degree data)

Investments · 61 tracked

founders shown can be your intro path

By year:2026 · 3 2025 · 2 2024 · 3 2023 · 2 2022 · 1 2021 · 2 2020 · 2 2019 · 2 2017 · 1 2016 · 1 2015 · 2 2014 · 223 dated

Edesa Biotechedesabiotech.com inNASDAQ: EDSA

Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases.

BiotechHealthtechMarkham, US

Pardeep Nijhawan(Executive Officer, Director)Stephen Lemieux(Executive Officer)inMichael Brooks(Executive Officer)Mary Catherine Brisson(Executive Officer)Mark A. McPartland(Executive Officer)Kathi Niffenegger(Executive Officer)in

Co-investorsVenture Ontario

X4 Pharmax4pharma.com in 𝕏NASDAQ: XFOR

X4 Pharmaceuticals is a biopharmaceutical company developing medicines for people living with rare immune disorders, including chronic neutropenia.

BiotechBoston, US

Mary DiBiase(Executive Officer)inChristophe Arbet-Engels(Executive Officer)inDavid Kirske(Executive Officer)inJohn Volpone(Executive Officer)inMark Baldry(Executive Officer)Adam Craig(Executive Officer, Director)in

Co-investorsBain Capital Life Sciences New Enterprise Associates (NEA)Partners Resolute Thynk Capital Omega Funds Polaris Partners

Zymeworkszymeworks.com in 𝕏NASDAQ: ZYME

Zymeworks is a biotechnology company that develops novel therapeutics for patients with difficult-to-treat diseases using its proprietary drug-development platforms and in-house R&D.

BiotechHealthtechVancouver, US

ALI TEHRANI(Executive Officer, Director)inGORDON NG(Executive Officer)NEIL KLOMPAS(Executive Officer)in SURJIT DIXIT(Executive Officer)inDAVID TUCKER(Executive Officer)Paul Moore(Chief Scientific Officer)in

Co-investorsBrace Pharma CTI Life Sciences Fund L.P.Nextech Invest WUTIF Capital Amplitude Venture Capital

Cadence Neurosciencecadenceneuro.com inFeb 2023 · $26M✓ verified

Cadence develops a neuromodulation system intended to be a more effective, less invasive treatment for people living with drug-refractory epilepsy.

BiotechDigital HealthHealthtechMedical DevicesSammamish, US

Kent Leyde(Executive Officer, Director, Promoter)inWarren Douglas Sheffield(Executive Officer, Director, Promoter)

Board seat Gerry Brunk· per SEC Form D

Co-investorsJAZZ Venture Partners Angelini Ventures F-Prime Capital Iaso Ventures

Spectrawavespectrawave.com in 𝕏Sep 2024✓ verified

SpectraWAVE develops optical and computational imaging technologies to diagnose and guide treatment decisions for patients with coronary artery disease and cardiovascular disease.

AI & Machine LearningDeep TechHealthtechMedical DevicesBedford, US

Eman Namati(President & CEO)inGuillermo Tearney(Founder; Professor of Pathology, Massachusetts General Hospital)Gregg Stone(Founder; Professor of Medicine, Mount Sinai Heart Health System)James Muller(Founder; Cardiologist, Brigham and Women's Hospital)inJeffrey O'Donnell(Founder; Managing General Partner, Runway Healthcare)Vivek Walimbe(Chief Operating Officer)in

Board seat Gerry Brunk· per SEC Form D

Co-investorsS3 Ventures SV Health Investors Deerfield Management Company Johnson & Johnson Innovation – JJDC

Biotheryxbiotheryx.com in✓ verified

Biotheryx is a clinical-stage biopharmaceutical company developing first-in-class targeted protein degraders, including molecular glues and bifunctional degraders, with an initial focus on cancer and inflammatory disease.

BiotechDeep TechMedical DevicesSan Diego, US

Kyle Chan, PhD(Executive Officer)Lawrence Zaslow(Executive Officer, Director)inFrank Mercurio, PhD(Executive Officer)Leah Fung(Chief Executive Officer & Board Member (former Chief Scientific Officer))in Raymond W. Urbanski(Acting Chief Medical Officer)inPhilippe Drouet(Chief Executive Officer)in

Co-investorsRevelation Partners SR One Capital Management

Cour Pharmacourpharma.com in 𝕏✓ verified

COUR develops antigen-specific immunotherapies that reprogram the immune system to treat the underlying causes of autoimmune and immune-mediated diseases while preserving normal immune function.

BiotechHealthtech

Co-investorsAlpha Wave Global Roche Venture Fund Angelini Ventures JDRF T1D Fund

Cyrano Therateuticscyranotherapeutics.com in✓ verified

Cyrano Therapeutics is a clinical-stage regenerative medicine company developing CYR-064, a nasal therapy for post-viral smell loss (hyposmia) and associated loss of taste.

BiotechDigital HealthHealthtechMedical DevicesDelray Beach, US

Rick Geoffrion(Founder, President and CEO & Board Member)in

Co-investorsRemiges Ventures, Inc.DeepWork Capital

Lqttrxlqttrx.com in 𝕏✓ verified

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra Odinkin Amy Sehnert in

Co-investorsAmzak Health adMare BioInnovations Alexandria CTI Life Sciences Fund L.P.

Puzzle Medicalpuzzlemed.com inApr 2025 · $43M✓ verified

Puzzle Medical develops a heart failure treatment device designed to improve heart and kidney function through 4Fr axillary access, allowing patient ambulation and providing up to seven days of support.

HardwareHealthtechMedical DevicesMontreal

Jade Doucet-Martineau(Co-founder & CEO, Board Director)inFrançois Trudeau(Co-founder & CTO, Board Director)inPhilippe Généreux(Co-founder (Phase 2), Chief Medical Officer & Board Observer)in Maxime Rochon(Co-founder (Phase 2) & VP Clinical, Regulatory and Quality)in Yves-Antoine Crête(Co-founder (Phase 2) & VP Technical R&D and Operations)inGabriel Georges(Co-founder & Clinical Advisor)in

Co-investorsBroadview Ventures Ajax Health Desjardins Capital Boreal Ventures Cathexis Ventures Front Row Ventures +1 more

Thryvtrxthryvtrx.com in 𝕏✓ verified

Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1).

BiotechDigital HealthMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra Odink(President & Chief Development Officer)in Amy Sehnert(Chief Medical Officer)in Matt Killeen(Chief Business Officer)in

BoardSaumya Das(Chief Scientific Advisor)

Co-investorsadMare BioInnovations Amzak Health CTI Life Sciences Fund L.P.Fonds de solidarité FTQ

Xylocorxylocor.com✓ verified

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.

BiotechHealthtechMedical DevicesMalvern, US

Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)

Board Glenn Batchelder(Director)inJames Cohen(Director)

Co-investorsFountain Healthcare Partners Jeito Capital Longwood Fund Sofinnova Ventures

Cyrano Therapeutics inNov 2020 · $9M

Develops regenerative therapy for persistent smell loss, currently in Phase 2 clinical trials.

HealthtechWashington, US

Richard Geoffrion(Executive Officer, Director)Robert Henkin(Director)

BoardTakahide Koda(Director)

Board seat Gerry Brunk· per SEC Form D

Co-investorsRemiges Ventures, Inc.DeepWork Capital

Endotronixendotronix.com in 𝕏Jul 2016

Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery pressure sensor and remote monitoring platform for managing patients with NYHA class III heart failure.

Digital HealthHealthtechMedical DevicesWoodridge, US

Harry Rowland(Executive Officer, Director)inAnthony I Nunez(Executive Officer, Director)inAnthony A. Nunez(Executive Officer, Director)inAnthony Nunez(Founder)in

BoardJonathan Jonas(Director)Raymond S. Barrett, Jr.(Director)

Board seat Gerry Brunk· per SEC Form D

Co-investorsBioventures Investors Jumpstart Ventures OSF Ventures Seroba Life Sciences SV Health Investors LSP (Life Sciences Partners)

Engage Therapeuticsengagetherapeutics.com in 𝕏Sep 2017

Company whose formation and launch the LifeSci team supported.

BiotechHealthtechSummit, US

Gregory Mayes(Executive Officer, Director, Promoter)Jouko Isojarvi(Executive Officer)Stephen D. Collins(Director)Warren Lammert(Director)inOrrin Devinsky(Director)

Board seat Gerry Brunk· per SEC Form D

Co-investorsLifeSci Venture Partners

Exact Imagingexactimaging.com in 𝕏Feb 2019

Exact Imaging develops the ExactVu micro-ultrasound platform, a 29 MHz imaging system that lets urologists perform real-time targeted and systematic prostate biopsies within a standard workflow.

HardwareHealthtechMedical DevicesMarkham, CA

Harold Wodlinger(Director)inRandy AuCoin(President & CEO)in Rob Sandler(Executive Officer)inJerrold Wen(Executive Officer)in

BoardWilliam Wortman(Director)Gaston Matthyssens(Director)

Board seat Peter van der Velden· per SEC Form D

Co-investorsiGan Partners PMV Venture Ontario Vesalius Biocapital Partners

HistoSonicshistosonics.com in 𝕏Apr 2019

HistoSonics develops histotripsy technology, a non-invasive method that uses focused sound energy to destroy targeted tissue, offered as a medical device for physicians and their patients.

BiotechHardwareHealthtechMedical DevicesAnn Arbor, GB

Thomas Davison(Executive Officer, Director)in M. Christine Gibbons(Executive Officer, Director)inWen Chen(Director)Tom Tefft(Director)Michael Blue(Executive Officer, Director)Fred Lee(Director)

Board seat Gerry Brunk· per SEC Form D

Co-investorsAlpha Wave Global Amzak Health Early Stage Partners, LP HealthQuest Capital Michigan Capital Network Bezos Expeditions +2 more

Pic Therapeuticspictherapeutics.comOct 2022SEC filingmedium confidence

BiotechBoston, US

Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)in

Board seat Gerry Brunk· per SEC Form D · $35M raise · filed Oct 2022

Co-investorsAdvent Life Sciences OrbiMed

Alpha-9 Oncologya9oncology.com inOct 2024

Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.

BiotechDigital HealthMedical DevicesVancouver, CA

François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)

Co-investorsAndreessen Horowitz Delos Capital General Catalyst Lightspeed Venture Partners Longitude Capital Nextech Invest +9 more

Alveolusbioalveolusbio.com in

Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD.

BiotechHealthtech

C Vivek Lal(Founder & CSO)inAmit Gaggar(Chief Medical Officer)in Gaurav Mehta(CEO)in

Amacatheraamacathera.ca in

AmacaThera is a biotech company developing a tunable injectable hydrogel drug-delivery platform, based on hyaluronic acid and methylcellulose, for localized and long-acting release of therapeutics such as small molecules, biologics, peptides, and cells.

BiotechDigital HealthMedical DevicesToronto, CA

Mike Cooke(Co-Founder & CEO)inMolly Shoichet(Co-Founder & Chief Science Officer)

Co-investorsStand Up Ventures Toronto Innovation Acceleration Partners

Antios Therapeuticsantiostherapeutics.com in 𝕏Nov 2021 · $75M

Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.

BiotechHealthtechMendham, US

Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)in Tamra Adams(Executive Officer)inAbel De La Rosa(Director)

BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)

Co-investorsAisling Capital Altium Capital Avego BioScience Capital Pontifax Venture Capital Amzak Health Delos Capital +8 more

Antiva Biosciencesantivabio.com inApr 2023 · $53M

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)in Gail Maderis(Director)in Kristine Ball(President & CEO)in Elaine Chien(Executive Officer)inSarah Walter(Executive Officer)in Raju Gadiraju(Executive Officer)in

Co-investorsAdjuvant Capital Brace Pharma Canaan Partners MPM BioImpact OUP (Osage University Partners)Sofinnova Ventures +3 more

Aurinia Pharmaceuticalsauriniapharma.com in 𝕏Feb 2014

Aurinia is a biopharmaceutical company developing therapies for autoimmune diseases with significant unmet medical needs.

BiotechDigital HealthHealthtechMedical DevicesVictoria, US

Richard M. Glickman(Executive Officer, Director)inStephen W. Zaruby(Executive Officer, Director)Michael Martin(Executive Officer, Director)inDennis Bourgeault(Executive Officer)Mr. Tang(Chief Executive Officer and Chair of the Board)

Board Kurt von Emster(Director)in

Co-investorsNew Enterprise Associates (NEA)venBio Partners

Axonis Therapeuticsaxonis.us inOct 2024

Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.

BiotechDeep TechBoston, US

Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)in Jeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in

BoardCorey . Goodman(Director)in Jonathan Leff(Director)in

Co-investorsvenBio Partners MRL Ventures Fund Sofinnova Ventures Civilization Ventures Management, Llc Creative Destruction Lab (CDL)Hatteras Venture Partners +7 more

Bardybardydx.com inAcquired

BardyDx develops the Carnation Ambulatory Monitor (CAM), a lightweight cardiac patch monitor designed for extended-wear ambulatory ECG monitoring that emphasizes P-wave signal clarity.

Digital HealthHealthtechMedical DevicesSeattle, US

Gust H. Bardy(Executive Officer, Director, Promoter)Mark Querry(Executive Officer)Kevin Nelson, III(Executive Officer)Rik Vandevenne(Director)Alan Levy(Director)Mark Handfelt(Executive Officer, Promoter)

Co-investorsAPERTURE Venture Partners Aphelion Capital Ascension Ventures RC Capital Rex Health Ventures SV Health Investors +1 more

Brightangeltherapeuticsbrightangeltherapeutics.com in 𝕏

Bright Angel Therapeutics is a pre-clinical stage biotechnology company developing small-molecule antifungal therapeutics aimed at drug-resistant and life-threatening invasive fungal infections.

BiotechDeep TechToronto, CA

Leah Cowen(Co-founder & CSO)Luke Whitesell(Co-founder & Consultant)Dominic Jaikaran(President & CEO)in

Co-investorsToronto Innovation Acceleration Partners

Cardiac Dimensionscardiacdimensions.com in 𝕏Mar 2025 · $53M

Cardiac Dimensions develops medical technology to treat heart failure caused by functional mitral regurgitation (FMR), aiming to address underlying causes rather than symptoms.

BiotechHealthtechMedical DevicesKirkland, US

Frederick A. Stewart(Executive Officer, Director)Rick Wypych(Executive Officer)in

BoardKurt Wheeler(Director)Nathan Every(Director)Douglas C. Fisher(Director)Gerry Brunk(Director)in

Co-investorsAPERTURE Venture Partners Redbus Ventures Ally Bridge Group Claret Capital Partners Jefferies M.H. Carnegie & Co.

Congruencetxcongruencetx.com in

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

Clarissa Desjardins(Founder)in

Co-investorsOrbiMed Alexandria DIMENSION BDC Thrive Venture Fund for Women

Contralinecontraline.com inMay 2026

Contraline develops new contraceptive and reproductive health technologies, with a focus on male contraception.

BiotechDigital HealthMedical DevicesCharlottesville, US

Kevin Eisenfrats(Co-Founder and CEO)inJohn Herr(Co-Founder)

BoardIris Van Alderwerelt van Rosenburgh(Director)Gurdane Bhutani(Director)inMartin J Emerson(Director)Tom Thorpe(Director)

Co-investorsBiotechnology Value Fund MBX Capital Allied Venture Partners Amboy Street Ventures Aurum Venture Partners Beni Venture Capital +14 more

Corviamedicalcorviamedical.com in 𝕏

Co-investorsAccelmed Partners

CV Therapeuticsgilead.com in 𝕏

Gilead discovers, develops, and delivers innovative therapeutics for people with life-threatening diseases, focusing on virology, oncology, and inflammation across more than 35 countries.

BiotechDigital HealthHealthtechMedical DevicesFoster City, US

Lou Lange(Founder)Michael L. Riordan(Founder)inDaniel O'Dayin

Co-investorsAisling Capital Asset Management Company Frazier Life Sciences Kleiner Perkins Longitude Capital Menlo Ventures +5 more

Damonapharmadamonapharma.com in

Damona develops precision neuromedicines aimed at treating cognitive deficits associated with neurodegenerative and psychiatric disorders such as Alzheimer's disease, depression, and schizophrenia.

BiotechDeep TechDigital HealthHealthtechMedical Devices

Co-investorsAngelini Ventures Noetic Toronto Innovation Acceleration Partners

Deka Biosciencesdekabiosciences.com

BiotechGermantown, US

John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)

Board Lu Han(Director)in

Co-investorsPlains Ventures Echo Investment Capital Leaps by Bayer MPM BioImpact

Endogenexendogenex.com in 𝕏

Endogenex is a clinical-stage medical device company developing the pulsENDO system, which applies non-thermal pulsed electric field to reset the body's metabolic signaling and improve function in people with type 2 diabetes.

Digital HealthHealthtechMedical DevicesMinneapolis, US

Stacey Pugh(Leadership (CEO))inChris Sorli, MD, PhD(Chief Medical Officer)inKrissy Wright(Chief Financial Officer)inLian Cunningham, MD, PhD(VP Clinical Affairs)in Melanie Hess(Regulatory Affairs Leadership)inMatt Cambronne(Technical/Engineering Leadership)in

Co-investorsArboretum Ventures Intuitive Ventures Longitude Capital

enGeneengene.com in 𝕏

enGene is a genetic medicine company developing drug therapies across oncology, urology, and other therapeutic areas, with a focus on patient outcomes.

BiotechMedical Devices

Co-investorsCTI Life Sciences Fund L.P.

Fusion Pharmaceuticalsfusionpharma.com in 𝕏

Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.

BiotechHealthtech

Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCap Seroba Life Sciences Venture Ontario Ysios Capital Adams Street Partners +2 more

G1 Therapeuticsg1therapeutics.comFeb 2015

G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.

BiotechResearch Triangle Park, US

Jay Strum(Executive Officer)Norman Sharpless(Director)Mark A. Velleca(Executive Officer, Director)inThomas K Laundon(Executive Officer)Timothy Sullivan(Director)Gregory Mossinghoff(Executive Officer)

Co-investorsMountain Group Capital RA Capital Solasta Ventures Hatteras Venture Partners

Guavatechnologiesguavatechnologies.com in 𝕏acquired by Cytek Biosciences

BiotechDeep TechHealthtechMedical DevicesBellevue, US

Iteriontherapeuticsiteriontherapeutics.com in

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway.

BiotechHealthtech

Rahul Aras(Chief Executive Officer)inOvid Trifan(Chief Medical Officer)inSteve Horrigan(Chief Scientific Officer)in

Co-investorsGreen Park & Golf Ventures Portal Innovations

Kisojibiotechkisojibiotech.com

KisoJi Biotechnology discovers and develops differentiated antibody therapeutics targeting difficult targets in oncology and other diseases.

AI & Machine LearningBiotechDeep Tech

Co-investorsRemiges Ventures, Inc.

Medexusmedexus.com in 𝕏

Medexus Pharmaceuticals is a specialty pharmaceutical company focused on orphan drugs and rare disease treatments, with a portfolio of specialty and rare disease products.

BiotechHealthtechToronto, CA

Nervoniknervonik.com inApr 2026 · $52.5M

Nervonik develops peripheral nerve stimulation (PNS) systems designed for high-motion, dynamic activity, using a patented technology that adds biosensing and objective feedback to neuromodulation.

HardwareHealthtechMedical Devices

Co-investorsFoothill Ventures ShangBay Capital LLC US Venture Partners Amzak Health

OncoMyx Therapeutics inDec 2021

BiotechPhoenix, US

Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)

Co-investorsB Capital Group Boehringer Ingelheim Venture Fund City Hill Ventures Delos Capital Korea Investment Partners LYZZ Capital +1 more

Opsensmedicalopsensmedical.com in 𝕏

OpSens Medical develops sensor-guided medical devices, including fiber optic guidewires and hemodynamic monitoring systems, for use in interventional cardiology procedures.

Digital HealthMedical Devices

Read the Press Releasestryker.com

Stryker is a medical technology company that develops and manufactures products across areas such as orthopaedics, surgical equipment, neurotechnology, and spine care for hospitals and healthcare providers.

Advanced ManufacturingHealthtechMedical Devices

Kevin Loboin

Co-investorsGefinor Capital New Enterprise Associates (NEA)Rex Health Ventures Windham Capital Partners

Sound Blade Medicalsoundblademedical.comJul 2026

SoundBlade Medical develops handheld histotripsy technology for non-invasive surgery, using focused ultrasound to treat tissue with precision.

HardwareHealthtechMedical Devices

Jeremy Brown(Co-Founder & CTO)inMatt Mallay(Co-Founder & Sr. Dir. R&D)in Andre Bezanson(Co-Founder & Dir. R&D)inEli Vlaisavljevich(Co-Founder)in Rick Balys(Co-Founder)inNeil Barman(Chief Executive Officer)in

Co-investorsAmzak Health APERTURE Venture Partners Invest Nova Scotia

Specificbiologicsspecificbiologics.com in

Specific Biologics develops in vivo genome editing therapeutics based on its Dualase editors, which use a two-site mechanism to remove, repair, or insert DNA sequences, with an initial focus on correcting expanded DNA repeats.

BiotechDeep TechHealthtech

Spinal Kineticsspinalkinetics.com in

HealthtechSunnyvale, US

Thomas Afzal(Executive Officer, Director)

Board Peter van der Velden(Director)inDavid Milne(Director)Dan Galles(Director)Mark Brooks(Director)Richard Ferrari(Director)

Co-investorsHLM Venture Partners SV Health Investors SV Life Sciences

Thinkresearchthinkresearch.com

Think Research works with health systems to improve care delivery through clinical software, clinical expertise, and hands-on operational support across access to care, clinical workflow, and medication safety.

Digital HealthHealthtechSaaS

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Celtaxsys Corvia MedicalMedexus PharmaceuticalsAssertiotxBauschEssapharmaForbiusGladius PharmaceuticalsKaipharmaceuticalsMorphotekResonantmedical

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 5

3 IPOs · 2 acquisitions · showing 4

Edesa BiotechNASDAQ: EDSAX4 PharmaNASDAQ: XFORZymeworksNASDAQ: ZYMEGuavatechnologiesacq. by Cytek Biosciences

Portfolio news

latest coverage across their companies

How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback

Aurinia Pharmaceuticals · finance.yahoo.com · Aug 20, 2026

enGene (NASDAQ:ENGN) Raised to "Sell" at Wall Street Zen

enGene · marketbeat.com · Aug 15, 2026

Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series B

Contraline · fiercebiotech.com · Aug 12, 2026

Cancer Breakthrough Fund Invests in Sound Blade Medical to Advance Handheld, Non-Invasive Histotripsy Therapy for Cancer | Morningstar

Sound Blade Medical · morningstar.com · Jul 29, 2026

[EFFECT] Edesa Biotech, Inc. SEC Filing | EDSA SEC Filing - Form EFFECT

Edesa Biotech · stocktitan.net · Jul 14, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

Congruencetx · geekwire.com · Jul 13, 2026

Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run

Zymeworks · finance.yahoo.com · Jul 1, 2026

Earnings call transcript: Medexus posts stronger Q4 2026 cash flow, stock slips By Investing.com

Medexus · investing.com · Jun 26, 2026

Public market activity · per SEC filings

what is this? ⓘ

enGene Holdings Inc.SC 13D/A

Disclosed stake · filed Feb 2024

view filing ↗

Edesa Biotech, Inc.SC 13D/A

Disclosed stake · filed Jan 2023

view filing ↗

SC 13D/A filingSC 13D/A

Disclosed stake · filed Jan 2020

view filing ↗

SC 13G/A filingSC 13G/A

Disclosed stake · filed Sep 2019

view filing ↗

SC 13D filingSC 13D

Disclosed stake · filed Aug 2019

view filing ↗

SC 13D filingSC 13D

Disclosed stake · filed Jun 2019

view filing ↗

SC 13G filingSC 13G

Disclosed stake · filed Feb 2018

view filing ↗

SC 13G filingSC 13G

Disclosed stake · filed Apr 2017

view filing ↗

8 insider ownership filings (Forms 3/4/5)

at enGene Holdings Inc. (ENGN), Edesa Biotech, Inc. (EDSA)

From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.

Frequently asked questions

How many investments has Lumira Ventures made?: Lumira Ventures has 61 tracked investments, 5 of which have exited, including 7 dated in the last 24 months.
What stage does Lumira Ventures invest at?: Lumira Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is Lumira Ventures's typical check size?: Lumira Ventures typically writes checks of $1M – $10M.
What sectors does Lumira Ventures focus on?: Lumira Ventures focuses on Biotech, Digital Health, Healthtech, Longevity, Medical Devices.
Where is Lumira Ventures located?: Lumira Ventures is headquartered in Toronto, CA.
Who does Lumira Ventures co-invest with?: Lumira Ventures most often shares deals with New Enterprise Associates (NEA), SV Health Investors, Toronto Innovation Acceleration Partners, among 108 tracked co-investors.

Images

Similar investors

Khosla Ventures

Khosla Ventures is a venture capital firm founded by Vinod Khosla.

$5K – $50M

Novo Holdings

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

OrbiMed

OrbiMed is a global healthcare-focused investment firm providing financing and operational support to companies across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services.

$1M – $75M

Foresite Capital

Foresite Capital is a healthcare-focused investment firm backing companies at the intersection of technology and biotechnology to personalize healthcare and accelerate medical innovation.

Pontifax Venture Capital

Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.

$6.3M – $128M